NCT05046847View on ClinicalTrials.gov

A Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB3811 Tablets in Patients With Advanced Malignant Tumors

PHASE1UnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 30, 2021

Primary Completion Date

October 31, 2022

Study Completion Date

December 31, 2022

Conditions
Solid Tumor
Interventions
DRUG

TQB3811

TQB3811 is a second-generation TrkA inhibitor.

Trial Locations (1)

100142

RECRUITING

Beijing Cancer Hospital, Beijing

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY